Literature DB >> 9226201

Is serum thyroglobulin a useful marker for thyroid cancer in patients who have not had ablation of residual thyroid tissue?

K Van Wyngaarden1, I R McDougall.   

Abstract

Serum thyroglobulin has been measured sequentially in 47 patients with differentiated thyroid cancer who had been treated by surgery and I-thyroxine, but no radioiodine (131I). In 39 of the patients, the operation was subtotal or total thyroidectomy, and in 8 patients it was lobectomy, or lobectomy plus isthmusectomy. In the first group of patients, serum thyroglobulin (Tg) was consistently undetectable in 62% and less than 5 ng/mL in 85%. In the latter group only 1 patient had undetectable Tg values and 2 (25%) had values less than 5 ng/mL. Even in those with higher Tg values, the levels remained constant within a narrow range, provided thyrotropin (TSH) was not high. Serum Tg can be used in conjunction with clinical evaluation in follow-up of patients with differentiated thyroid cancer who have had an operation consisting of more than lobectomy and isthmusectomy and have not been treated with 131I. Its use in patients with lesser operations has to be interpreted in relation to the amount of thyroid left and to the consistency of the results with time.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9226201     DOI: 10.1089/thy.1997.7.343

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  1 in total

1.  Prognostic Impact of Direct 131I Therapy After Detection of Biochemical Recurrence in Intermediate or High-Risk Differentiated Thyroid Cancer: A Retrospective Cohort Study.

Authors:  José F Carrillo; Rafael Vázquez-Romo; Margarita C Ramírez-Ortega; Liliana C Carrillo; Edgar Gómez-Argumosa; Luis F Oñate-Ocaña
Journal:  Front Endocrinol (Lausanne)       Date:  2019-10-29       Impact factor: 5.555

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.